Expression of androgen receptors in primary breast cancer.
about
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamideProlactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancerTargeting androgen receptor in estrogen receptor-negative breast cancerPhase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast CancerTamoxifen Resistance: Emerging Molecular TargetsEpithelial-Mesenchymal Transition (EMT) and Regulation of EMT Factors by Steroid Nuclear Receptors in Breast Cancer: A Review and in Silico InvestigationThe fate of chemoresistance in triple negative breast cancer (TNBC)Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysisTargeting the androgen receptor in prostate and breast cancer: several new agents in developmentPhospho-kinase profile of triple negative breast cancer and androgen receptor signaling.Prolactin/Stat5 and androgen R1881 coactivate carboxypeptidase-D gene in breast cancer cellsEstrogen and androgen-converting enzymes 17β-hydroxysteroid dehydrogenase and their involvement in cancer: with a special focus on 17β-hydroxysteroid dehydrogenase type 1, 2, and breast cancer.Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.Prolactin-induced protein is required for cell cycle progression in breast cancer.Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?Expression of the Androgen Receptor, pAkt, and pPTEN in Breast Cancer and Their Potential in Prognostication.Androgen receptor expression and breast cancer survival in postmenopausal women.Androgen receptor genotypes predict response to endocrine treatment in breast cancer patients.Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associationsFrequent copy number gains at 1q21 and 1q32 are associated with overexpression of the ETS transcription factors ETV3 and ELF3 in breast cancer irrespective of molecular subtypes.Treatment options for patients with triple-negative breast cancerIs the future of personalized therapy in triple-negative breast cancer based on molecular subtype?Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancerAndrogen receptors and serum testosterone levels identify different subsets of postmenopausal breast cancers.A Tale of Two Signals: AR and WNT in Development and Tumorigenesis of Prostate and Mammary Gland.A feedback loop between androgen receptor and ERK signaling in estrogen receptor-negative breast cancer.Making sense of intratumor genetic heterogeneity: altered frequency of androgen receptor CAG repeat length variants in breast cancer tissues.Coagulation factor VII is regulated by androgen receptor in breast cancer.Dietary lignan intake and androgen receptor expression in breast tumors.Triple-negative breast cancer: new perspectives for targeted therapies.Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options.Management options in triple-negative breast cancerAndrogen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1.Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer.Androgen Receptor (AR), E-Cadherin, and Ki-67 as Emerging Targets and Novel Prognostic Markers in Triple-Negative Breast Cancer (TNBC) PatientsExpression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients.Influence of Androgen Receptor Expression on the Survival Outcomes in Breast Cancer: A Meta-AnalysisIn-silico identification and functional validation of allele-dependent AR enhancers.Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy.
P2860
Q21195191-48174CBF-2868-4F29-AFE1-D751A61812BCQ21195199-B029F293-D56F-476C-904A-B6D383BC7306Q24312457-F0487D62-7CC1-4E99-B4A3-52C66F6F0C91Q24563045-46136B33-F175-48C2-B8D0-4F7F4A59DF0DQ26739969-84495D1A-94E6-452C-861E-733A55D2A6FCQ26770051-251F95A1-4467-4663-9C7E-156CEE4F0F3EQ26775232-B4D5B32D-D0EE-4A0B-B1DB-FE478743C785Q26823419-21E0DF00-4EFE-45AD-8BE4-496D7607E646Q27009424-8EE9A204-24D3-4316-A355-693F810BF87CQ33612132-C7CA2F6E-F31D-4111-B635-38217DFF4641Q33632218-B472012A-C200-4544-B33E-49AFF20BECACQ33728381-D0BA731D-FA0B-48CF-B6D3-CEFC4424B12AQ33739841-F9C6A92A-937D-4244-A443-F6E39B8285D9Q33891258-EAC5FDBD-BDE5-48E5-B97D-CB222EE96981Q33932665-51E3AB98-E702-429B-9C57-0B8E3561569DQ34092016-960412C5-5552-4E15-BB97-3036738B904FQ34164902-C241433E-32BD-4990-B7B0-E0392B2CCE1DQ34228066-5F6382BA-5781-4C1D-B74C-F0561CE48C56Q34309894-AA8BA192-195B-44ED-8C59-C2CA0B6ACC68Q34323234-F3C28A03-9275-4FBA-9B80-BEA43AFEED3BQ34331406-29A64C50-F011-4A08-BCEE-E2BEC9780700Q34476337-44B52596-A934-4BEB-A051-778B1F4E8B45Q34499512-4BCCC8FF-EFF3-4DDF-B3B1-9950FB0F77D0Q34512957-5333A7DC-6C19-4CB7-8261-3A5540BE7200Q34550256-2ACEB533-EBF4-4AE3-B6DC-24B52660C3E8Q34551559-2AFAC154-811F-4BBB-95B4-141941E8FFBDQ34573232-BAACA2F1-3AC9-40C3-B628-A5FC610E9139Q34995790-BE8D7EFA-82D0-477C-B92D-D3EFA5C78FF5Q34995845-9D5F9D4B-286B-4C47-A61E-0183ECC25164Q35001758-6157B4D6-F8DE-497D-8399-580174D9CB14Q35088745-28BCA630-0409-4C76-961C-F18C929EE525Q35155460-91CC19BD-2A01-4D5E-A15C-A14E308F53B8Q35176984-BF0F0761-5EA0-4171-B723-365909F20584Q35558993-2BE80470-F954-4690-8386-6A24C1DB1272Q35651216-D370456F-A291-4191-A74C-80DCC559ACBBQ35668330-34178C79-16C7-457A-B967-0D4F3F21D067Q35686249-60AE4BD9-6DF7-49A7-BFFC-00B11CC35355Q35741562-A76776A3-512B-4EFA-8E61-C5DCA43817DDQ35892429-302A1C0F-F02B-49A1-8023-562B2B10DFB9Q35894728-1FDDCC80-6B9D-4262-9015-F8FA27EB5898
P2860
Expression of androgen receptors in primary breast cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Expression of androgen receptors in primary breast cancer.
@en
Expression of androgen receptors in primary breast cancer.
@nl
type
label
Expression of androgen receptors in primary breast cancer.
@en
Expression of androgen receptors in primary breast cancer.
@nl
prefLabel
Expression of androgen receptors in primary breast cancer.
@en
Expression of androgen receptors in primary breast cancer.
@nl
P2093
P2860
P356
P1433
P1476
Expression of androgen receptors in primary breast cancer.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDP510
P577
2009-11-03T00:00:00Z